Rani Therapeutics appointed Nicholas M. Maestas as Chief Financial Officer effective June 29, 2026, succeeding Svai Sanford who stepped down upon the appointment of his successor.
| IndividualNicholas M. MaestasSvai Sanford | RoleChief Financial Officer (principal financial officer and principal accounting officer)Chief Financial Officer (prior) | Type of ChangeAppointedResigned/Stepped down | Effective DateJune 29, 2026June 29, 2026 (upon appointment of successor) | ReasonNot disclosedCompany previously announced he would be stepping down upon appointment of his successor | Replacement InfoN/ASucceeded by Nicholas M. Maestas | Background DetailsAge 46; former CFO & Head of Corporate Strategy of Tempest Therapeutics (Jan 2025–Jun 2026); prior roles at Tempest (VP, Finance & Strategy), Alector (head of FP&A & strategic finance), Immune Design; BA UC Berkeley; MBA Wharton.Not disclosed | Board/Committee Role ChangesNot disclosedNot disclosed |
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.